Our scientists are developing a new experimental drug to target how cancer cells repair their DNA, and upset cancer’s balance.
As many as 1 in 5 women with breast cancer could benefit from a drug used to treat ovarian cancer, according to new estimates.
A genetic flaw that’s often found in a type of brain tumour may stop the cells from fixing damage to their DNA, findings from a new US study suggest.
Last week we had the pleasure of awarding our Research Prizes to five exceptional researchers at our annual prizegiving ceremony at the NCRI Conference.
The year is 2016, Breast Cancer Awareness Month is upon us, and right now, 8 in 10 women diagnosed with breast cancer will survive their disease for 10 years or more.
Cancer Research Technology (CRT) and SV Life Sciences have today announced the launch of Artios Pharma.
Research by our scientists played a major part in the development of a promising new class of cancer drugs. So where are we now in this research journey?
Scientists have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments.
Recent research has reinforced the need for all women with ovarian cancer to receive genetic testing, but they aren’t. We explore why.